Andre Xiao

Andre joined Sofinnova BioEquities as a Senior Analyst in 2023. He focuses on public investments primarily in Medtech and Life Sciences.

Prior to Sofinnova, Andre was an Analyst at Perceptive, where he was focused on the same verticals. Before Perceptive, Andre was at Citadel, where he managed a market-neutral Medtech/Life Sciences portfolio.

Andre received his Bachelor’s degree from the Wharton School, where he graduated in two years, Summa cum Laude. Additionally, he completed two Master’s degrees – simultaneously – at MIT (MBA – Finance), and Harvard (MPH – Infectious Diseases).